Trial Profile
Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy or are receiving a LHRH analogue
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bayer HealthCare
- 16 Aug 2012 New trial record